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INTRODUCTION 
Some studies have recently shown that the number of tumor markers (TMs) requested is considerably 
higher than expected based on cancer prevalence (1,2), and that many factors may contribute to 
overordering of laboratory tests (3). These findings are in agreement with studies performed in case series 
showing that TMs are frequently requested inappropriately (4). The high rate of overutilization is related to 
an increased risk of both overdiagnosis and false positive results, with significant repercussions both on 
individual patients and health care systems (5). 
The pathway of knowledge translation of TM research results to clinical practice has changed over the 
years. Until a couple of decades ago, primary studies were considered the major source of information for 
clinical practice; studies reporting promising results were frequently advocated to sustain the utilization of 
the marker. Over the last 2 decades – also because of a progressive shrinkage of resources allotted to the 
health care sector – clinical practice guidelines (CPGs) have been more and more frequently considered the 
reference evidence to support clinical choices. However, it should be noted that the primary studies 
concerning TMs frequently lack design requirements needed to provide good-level evidence according to 
criteria set for therapeutic intervention trials. Randomization and blinding methods are applied in only few 
studies where a TM is used as a predictive marker to select patients for a given therapy. The majority of 
studies on TMs evaluate the diagnostic or prognostic information provided by the markers in a 
nonrandomized manner; in the case of determination of circulating tumor markers, whichever the result 
may be, it has no immediate impact on clinical decision-making. As a result, panels preparing CPGs typically 
lack high-level evidence on TMs according to standard requirements for intervention trials; they frequently 
either do not produce recommendations, or opt for formulating negative recommendations. 
Nevertheless, in spite of either available negative recommendations or the absence of recommendations, 
TM overordering persists and tends to increase over time, demonstrating the poor adherence of clinicians 
to CPGs. Many barriers may prevent clinicians from following guideline recommendations, including 
discrepancies between promising results of primary studies and the cautious position of CPGs, and the 
frequent poor consistency between recommendations prepared by different CPGs on the same clinical 
question.  
Diagnostic randomized controlled trials are still infrequently performed, and although the number of 
comparative diagnostic test accuracy studies is increasing, the vast majority of the available evidence 
comes from single test evaluation studies. The latter studies do not measure patient-relevant outcomes 
directly, and cannot be equated to pharmacological clinical trials due to intrinsic differences in both design 
and endpoints. Although a framework of “linked evidence” has been in place for years, which strives to use 
evidence on true positive, true negative, false positive and false negative test results to deduct therapeutic 
and other patient-relevant consequences of testing, the application of this framework has been shown to 
be challenging (6). While awaiting the distillation of higher quality evidence into comprehensive guidelines 
with possibly an application of the linked-evidence or related frameworks (7), efforts should be made to 
improve the adherence to existing guidelines. 
Harmonization of different CPGs is a current strategy to handle uncertainties or discrepancies between 
different CPGs in settings where the clinical questions are complex, e.g., screening programs or disease 
prevention campaigns. Studies on the harmonization of recommendations for circulating cancer biomarkers 
have not been published so far. 
The aim of the present research project is to develop a tool to summarize the recommendations and 
supplementary information on circulating TMs offered by available CPGs on solid tumors. The tool is 
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intended to provide all possible evidence-based choices concerning TMs for people facing a clinical 
question in which the use of a TM could be contemplated.  
Diligence was adopted to develop the tool according to a structured and rigorous methodology in order to 
guarantee the accurate extraction of relevant information including recommendations from selected 
guidelines as well as the validity of the synthesis of information from different sources. 
Recommendations and supplementary information extracted from CPGs were clustered and summarized 
applying 4 increasing levels of synthesis, summarizing and simplifying the information to make it explicit, 
verifiable, valid and reproducible. The first 2 levels of clustering and synthesis are available for consultation 
upon request. The last 2 levels of synthesis are reported in the present article. They are the Detailed 
Summary Tables and Take-Home Messages, which represent the levels of synthesis suitable for practical 
use. The Take-Home Messages are intended for use by health care providers in clinical practice with the 
goal of improving the appropriateness of TM use. The Detailed Summary Tables can be used by policy 
makers for potential adaptation to their own context and by educators to design teaching programs 
consistent with the available evidence. 
The tabulation of the information has been structured by individual malignancies. Within each malignancy, 
we clustered the information according to a set of clinical questions established as being common to all 
malignancies. A parallel assessment of the quality of the included CPGs has been performed and the results 
are shown alongside the Take-Home Messages in order to inform the reader about the quality of the 
source (CPGs) from which the recommendations were distilled.  
The purpose of this project was to provide an accurate and synthetic reproduction of the available evidence 
on the clinical use of circulating TMs. We endeavored to avoid any interpretation of the content of CPGs 
and used verbatim reporting of the original sentences whenever possible.  
Likewise, the expert panel intentionally avoided expressing its own opinion in cases where different CPGs 
showed discrepant positions on a clinical question. Dissimilar recommendations of diverse CPGs may be 
due to different causes; in fact, CPG panels have to interpret the primary TM evidence in different local 
contexts with possibly dissimilar available resources or patient preferences. Our panel deemed that the 
complete presentation of clinical questions in which the consistency between guidelines seemed poor 
represents a strength of the present project for 2 reasons; firstly, it provides an inventory of all possible 
recommendations after the application of evidence synthesis frameworks; secondly, it should help identify 
areas in which primary studies are especially needed to answer clinical questions concerning TMs.  
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METHODOLOGY 
Scope 
CPGs are critical for translating evidence to application in medical decision-making. Trustworthy guidelines 
are based on a systematic review of the clinical evidence (1, 2). The number of CPGs has grown 
considerably and their quality is often heterogeneous. The objective of the project was to provide an easy-
to-use but complete synthesis of TM recommendations distilled from evidence-based CPGs. The ultimate 
aim was to improve the appropriate use of TMs in clinical practice.  
For the synthesis document to be useful it had to have the following characteristics: 
− to be developed with sound and structured methodology 
− to include all recommendations and information on circulating biomarkers reported in CPGs on solid 
tumors 
− to synthesize recommendations and information in easy-to-use tables at 2 decreasing levels of 
complexity 
− to be useful for the following target audience: (i) health care providers, (ii) policy makers for potential 
adaptation to specific settings, and (iii) staff developing educational material informed by available 
evidence. 
Panel composition and project planning 
The participating institutions and scientific societies suggested 74 delegates to be enrolled in the expert 
panel. The panel comprised a multidisciplinary group of medical oncologists, radiation oncologists, clinical 
pathologists, general practitioners, internists, gynecologists, urologists, and experts in evidence-based 
methodology.  
The project was organized in work packages (WPs) with dedicated tasks and milestones: 
WP1 – Definition of the primary objectives of the project and management strategies 
WP2 – Search and selection of guidelines 
WP3 – Appraisal of guidelines through the AGREE II tool 
WP4 – Assessment of the rate of utilization of a subset of guidance documents in clinical practice 
WP5 – Synthesis into “Detailed Summary Tables” and “Take-Home Messages” regarding the recommended 
use of TMs 
WP6 – Assessment of the correctness and completeness of the information summarized in the summary 
tables by our expert panel (n=74) 
WP7 – External and independent verification of the correctness and completeness of the information 
summarized in the tables by an independent external committee (n=18). 
WP1 was jointly managed by the Steering Committee and the Scientific Committee of the project. The 
activities of WPs 2 to 6 were carried out by working groups composed of members of the expert panel, in 
which oncologists and other clinicians, laboratory staff, methodologists and other research staff 
participated (see pp. 1-2). WP7 was realized by the members of the Interregional Biomarkers Working 
Group, instituted by the Health Commission of the Italian Permanent Conference for Relations between 
State, Regions and the Autonomous Provinces of Trento and Bolzano. 
Search and selection process 
We performed a systematic search for CPGs in the following databases: PubMed, the National Guidelines 
Clearinghouse and the GIN library. The search for guidance documents included the following search terms, 
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their synonyms, and associated MESH terms: "guideline OR recommendation OR consensus OR consensus 
development conference" AND "neoplasms OR carcinoma OR cancer OR tumor". We included guidance 
documents published from January 2009 to July 2015 in English or Italian. The search identified a total of 
8,266 citations. In addition to searching bibliographic databases, we searched 11 websites of state or local 
government agencies and 61 websites of pertinent professional organizations in Italy. 
We used a standardized set of selection criteria to identify potentially relevant publications. The identified 
documents were assessed for pertinence according to shared criteria established by a selected group of 4 
members of the expert panel to select guidelines that fit the objectives of the project. 
Only documents containing recommendations for clinical practice were included. Reviews, technology 
assessments, commentaries to CPGs, and service documents were excluded. The types of biomarker 
considered were circulating biomarkers measured in body fluids (blood derivatives of serum or 
plasma/urine) with commercially available assay methods. Fecal blood tests, laboratory tests aimed at 
monitoring metabolism, organ damage and blood cell counts were not considered, as these do not present 
a direct relationship with the tumor. Circulating tumor cells, cell-free circulating DNA, and microRNA were 
also excluded from the assessment. Guidance papers limited to rare tumors, sarcomas, hematological 
malignancies, the pediatric population, pregnant women, and specific aspects of specialized topics (i.e., 
imaging techniques, radiotherapy procedures, drug administration modalities) were excluded. We did not 
consider health care procedures established by the Italian National Health Service at the national and 
regional level (i.e., hereditary tumors other than those of the ovary and thyroid), nor did we consider 
screening programs currently provided by the Italian National Health Service (i.e., screening for colorectal 
cancer, uterine cervix cancer and breast cancer), as the latter do not include circulating TMs. Details on the 
search strategy and selection criteria will be described in a dedicated report on the systematic review 
process (in preparation and available from the corresponding author of the present article). 
Selection of CPGs was independently performed by 3 examiners on the basis of the titles and abstracts of 
the 8,266 identified documents. A guidance document was considered potentially relevant when 2 of the 3 
examiners opted for inclusion. Documents included by a single examiner were discussed until consensus for 
inclusion or exclusion was reached. 
A total of 1,181 potentially relevant documents were selected, for which full-text reports were obtained. 
The resulting set was then screened for inclusion and the included reports were grouped by guideline, 
allowing multiple reports on a single guideline. If several versions of a specific guideline were found, we 
included the most recently updated version.  
We included a final set of 559 CPGs concerning 20 different malignancies: carcinomas of the breast, biliary 
tract, colon-rectum, endometrium, esophagus, head and neck, kidney, liver, lung, stomach, ovary, 
pancreas, prostate, uterine cervix, urinary bladder, differentiated and medullary thyroid cancer, germ cell 
testicular cancer, melanoma, mesothelioma and neuroendocrine tumors. 
Quality appraisal of guidelines 
The selected guidance documents were further appraised to determine their adherence to the IOM 
standards, which require CPGs to be based on systematic reviews of existing evidence (1). The 559 
guidance documents were clustered into 2 groups: 127 documents in which systematic reviews were 
essential to generate recommendations (CPGs) and 432 guidance documents without evidence of 
systematic review methodology (other guidance documents – OGDs). However, authoritative institutions or 
medical societies typically produce guidance documents without applying systematic review methods. We 
also knew up front that these documents are currently used by clinicians in their daily practice. The 
Steering Committee therefore decided to provide all guidance documents to the panel members with a 
request to judge which of the OGDs were used by our target audience. Whenever 25% or more of the panel 
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members declared that a given guidance document was used in clinical practice, the guidance document 
was retained. In all, 111 of 432 OGDs qualified for inclusion. 
The development process 
The detailed process of document development was agreed upon by the Steering Committee and the 
Scientific Committee (report in preparation and available from the corresponding author of the present 
article). The basic steps in the process are summarized below: 
– classifying the clinical questions (e.g., screening, diagnosis, therapy)
– choosing the biomarkers of interest
– developing the specific queries on TM use within the clinical questions
– retrieving and tagging information concerning every clinical question
– data extraction from both types of guidance documents, with quality assessment of CPGs and
assessment of clinical use of OGDs
– clustering and synthesizing information at decreasing levels of complexity
– final write-up
Classifying the clinical question 
Given that the role of TMs may differ widely in the different clinical phases of the disease, we decided to 
consider the clinical questions separately: (i) screening, (ii) differential diagnosis, (iii) preoperative workup, 
(iv) reassessment after curative treatment, (v) early detection of recurrence or progression, and (ii)
monitoring of treatment response in advanced disease. Details of the considered clinical questions are
reported elsewhere (in preparation and available from the corresponding author of the present article).
Developing specific queries within the clinical questions  
The information related to the following specific queries were found in the selected guidance documents: 
1. Is the use of TM(s) explicitly recommended or not recommended?
2. Which TM(s) is/are recommended or not recommended?
3. In which type of patients is/are TM(s) recommended or not recommended?
4. Can TM(s) be used autonomously or should they be used in association with other tests?
5. Are rules to interpret the result of TM determination provided?
6. Do the TM results have an impact on treatment decisions or, more broadly, on the clinical management
of the patient?
7. Is information on possible causes of false positive and false negative results provided?
8. Is information on preanalytical or analytical issues that can influence the reliability of the TM result
provided?
Retrieving and tagging information concerning every clinical question  
For every malignancy, all information concerning TMs in the different clinical questions was identified in 
the selected guidance documents. For each guidance document, the relevant information was tagged, 
extracted (whenever possible as a verbatim transcription) and classified as follows: 
− Recommendation: part of text explicitly defined and clearly recognizable as recommendation 
− Supplementary information: (i) implicit advice for clinical practice not recognizable as explicit 
recommendation; (ii) additional information concerning the application and interpretation of TMs 
− Supporting evidence: reporting and conclusions of the evidence used by the author team that 
developed the published guidance document to draw up recommendations. 
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All information extracted from guidance documents was clustered and synthesized in 4 rounds (levels) of 
increasing simplification as described elsewhere (report in preparation and available from the 
corresponding author of the present article) and briefly summarized below.  
− Level 1: The parts pertaining to TMs were retrieved from every guidance document and transcribed 
verbatim, preserving the textual structure – e.g., paragraph, complete clause – in which they were 
included, in a Master table (first-level tabulation) 
− Level 2: Portions of text strictly referring to TMs were extracted, clustered as recommendations and 
supplementary information, and transcribed verbatim in a table (second-level tabulation). Information 
from different guidelines was summarized separately 
− Level 3: Similar recommendations and supplementary information from different guidelines were 
summarized as a single entry, followed by the acronyms of the CPGs and/or ODGs formulating them 
(third-level tabulation: Detailed Summary Table) 
− Level 4: Essential information to support decision-making in clinical practice was distilled and 
summarized in a further simplified table (fourth-level tabulation: Take-Home Message). 
The present article reports the Detailed Summary Tables and Take-Home Messages, which represent the 
levels of synthesis suitable for practical use. 
Managing information of CPGs and OGDs 
Recommendations provided by CPGs are displayed in Detailed Summary Tables and Take-Home Messages. 
Recommendations from OGDs are embedded in both tables whenever they were consistent with those of 
CPGs. Recommendations reported exclusively by OGDs are not included in the Take-Home Messages, but 
are provided as supplementary information in the Detailed Summary Tables. CPGs and OGDs are labeled as 
such in all tables in order to allow the reader to track the source of the reported information. 
Wording 
The terms used to formulate recommendations were found to be highly heterogeneous among the 
included guidelines, reflecting (i) the variable quality of the supporting evidence, (ii) the different weight 
given to the trade-off between the benefits and harms of an intervention in different contexts, and (iii) the 
uneven methodological rigor used to develop the guidance documents. In agreement with the scope of the 
project, the Scientific Committee settled on maintaining the original terms used by different CPGs, thus 
avoiding any attempt towards harmonization of the terms. When the same recommendation was provided 
by more than one CPG, the less stringent term (e.g., should rather than have to) was chosen in the 
synthesis. 
Indications concerning TMs can be grouped into 3 categories: positive recommendation (CPG recommends 
to use TM), negative recommendation (CPG recommends not to use the marker), and no explicit 
recommendation available. The third category (no explicit recommendation available) encompasses 
different circumstances in relation to either the availability and quality of evidence or the assessment of 
benefit and harms, or both. 
The following sentences were used in the synthesis to represent the different circumstances in which no 
recommendations were provided: 
1. Clinical question considered, but TMs not addressed: The clinical question (screening, differential
diagnosis, initial workup, etc.) is comprehensively considered by the CPG, but circulating TMs are not
mentioned.
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2. Clinical question considered, no explicit recommendations on TMs provided: TMs are mentioned and
discussed with reference to the clinical question, but the panel that developed the CPG deemed the
available evidence or the assessment of benefit and harms, or both, not adequate to support a positive
or negative recommendation.
3. Clinical question considered, but criteria to monitor treatment response (including TMs) not addressed:
Response rates to different therapeutic regimens and survival benefits are the most frequently
addressed topics by guidance documents in the clinical question “Monitoring of treatment response in
advanced disease”. If the guidance document does not mention criteria to monitor the response, it
cannot be assumed that a systematic search of the primary literature on TMs in this setting was
performed. Therefore, a sentence different from the first one was used since it could not be appraised
whether the clinical question had been comprehensively considered.
These 3 sentences are used in the Detailed Summary Tables to provide comprehensive information on how 
different guidelines considered TMs in different clinical questions. In the Take-Home Messages a more 
general sentence indicating that there are no recommendations on TMs was preferred (Recommendations 
on TMs not available), given the practical purpose of this level of synthesis. 
Agreeing on the synthesis process and results 
The process of synthesis was agreed upon within the Scientific Committee. The Detailed Summary Tables 
and Take-Home Messages were submitted to the expert panel for evaluation (internal evaluation) and 
approval of the synthesis, or for suggestions. Comments and suggestions were discussed and accepted 
when appropriate. The Detailed Summary Tables and Take-Home Messages were then submitted to the 
members of the Interregional Biomarkers Working Group, instituted by the Health Commission of the 
Italian Permanent Conference for Relations between State, Regions and the Autonomous Provinces of 
Trento and Bolzano for external and independent verification of the correctness and completeness of the 
information summarized in the tables. 
Assessment of CPGs with the AGREE II instrument 
CPGs were assessed with the Appraisal of Guidelines for Research & Evaluation (AGREE II) tool, in order to 
facilitate comparison of the quality of the summarized CPGs on the basis of an objective, standardized 
method (3). The instrument comprises 23 key items organized into 6 domains. Each domain captures a 
distinct dimension of guideline quality: 1. Scope and purpose; 2. Stakeholder involvement; 3. Rigor of 
development; 4. Clarity of presentation; 5. Applicability; 6. Editorial independence. An AGREE quality score 
is calculated for each of the 6 AGREE domains using a 7-point scoring system. A higher score indicates a better 
quality of the domain. The 6 domain scores are independent and should not be combined into a single score. 
Each CPG was rated by 2 evaluators independently. If the CPG addressed multiple diseases, the evaluators 
considered the documents as many times as the number of diseases addressed. The evaluators achieved high 
interrater reliability. The scores of the 6 domains were subdivided into quartiles and marked in different 
colors for easier comprehension of the score (4). 
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TAKE-HOME MESSAGES 
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TAKE-HOME MESSAGES - Users’ instructions 
Definition and target audience 
Take-Home Messages are presented in table format for every tumor type, summarizing essential information to support decision-making in clinical 
practice. They are intended for use by health care providers. 
Structure 
Total number of selected documents (number of CPGs, number of OGDs) 
Clinical question Summary of recommendations Recommended tumor marker(s) 
CPG/total CPG 
(CPG acronyms) 
OGD/total OGD
(OGD acronyms) 
The different clinical 
questions are 
reported 
The symbol  
denotes that CPGs 
formulated 
inconsistent 
recommendations on 
TMs in the clinical 
question 
Recommendations and information 
from CPGs that consider the clinical 
question are summarized 
The sentence “Recommendations on 
TMs not available” is reported when 
the clinical question was considered by 
CPGs, but either TMs were not 
addressed or no explicit 
recommendations on TMs were 
provided 
The recommended TM(s) are 
reported 
When CPGs explicitly 
recommend against TM(s), the 
word “None” is reported 
The symbol ∅ is shown when 
the examined CPGs either do 
not address TMs or, if TMs are 
addressed, CPGs do not 
formulate explicit 
recommendations 
Number of CPGs 
reporting the 
summarized 
information in 
proportion to the 
total number of CPGs 
that consider the 
clinical question 
(acronyms of the 
CPGs in parenthesis) 
Number of ODGs 
reporting the 
summarized 
information in 
proportion to the 
total number of CPGs 
that consider the 
clinical question 
(acronyms of the 
OGDs in parenthesis)  
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AGREE evaluation 
CPGs concerning every malignancy were also assessed with the Appraisal of Guidelines for Research & Evaluation (AGREE II) tool. A higher score 
equals a better quality of the domain. The results are reported after the Take-Home Message tables.  
Acronym Domain 1 
Scope and purpose 
Domain 2 
Stakeholder 
involvement 
Domain 3 
Rigor of 
development 
Domain 4 
Clarity of 
presentation 
Domain 5 
Applicability 
Domain 6 
Editorial 
independence 
Acronyms 
of CPGs 
Scores concerning 
the overall aim of 
the guideline, the 
specific health 
questions, and the 
target population 
are reported for 
every CPG 
Scores concerning the 
extent to which the 
guideline was 
developed by the 
appropriate 
stakeholders and 
represents the views 
of its intended users 
are reported for every 
CPG 
Scores concerning 
the process used to 
gather and 
synthesize the 
evidence, and the 
methods to 
formulate the 
recommendations 
and update them are 
reported for every 
CPG 
Scores concerning 
the language, 
structure, and 
format of the 
guideline are 
reported for every 
CPG 
Scores concerning the 
likely barriers and 
facilitators to 
implementation, 
strategies to improve 
uptake, and resource 
implications of 
applying the guideline 
are reported for every 
CPG 
Scores concerning 
the formulation of 
recommendations 
not being unduly 
biased with 
competing 
interests are 
reported for every 
CPG 
The scores of the 6 domains were subdivided into quartiles and marked in different colors as shown in the following table: 
0-25th percentile
26th-50th percentile 
51st-75th percentile 
76th-100th percentile 
Additional notes 
− Take-Home Message tables are reported in alphabetical order  
− Information from OGDs on a specific clinical question were only reported in the Take-Home Message table if the clinical question was considered 
by CPGs. Descriptions regarding these OGDs can, however, be found in the Detailed Summary Tables. 
− References concerning both GPGs and OGD are reported after the Detailed Summary Tables, divided by type of malignancy and cited with the 
acronyms used in the Tables 
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Biliary cancer Examined documents: 7 (2 CPGs, 5 OGDs) 
Clinical question Summary of recommendations Recommended tumor marker(s) 
CPG/total CPG (1) 
(CPG acronyms) 
OGD/total OGD (2)
(OGD acronyms) 
Screening of people 
at increased risk 
(sclerosing 
cholangitis) 
Recommendations on TMs not available ∅ 1/1 (ACG 2014) 
1/2 
(AASLD 2010) 
Differential 
diagnosis Recommendations on TMs not available ∅ 
2/2 
(ACG 2014, NICE 2015) 
4/5 
(AIRO 2012, ESMO 2011, 
NCCN 2015, SIGE 2010) 
Preoperative 
workup Recommendations on TMs not available ∅ 
1/1 
(ACG 2014) 
1/3 
(SIGE 2010) 
Reassessment after 
initial curative 
treatment 
Clinical question not addressed by CPGs --- --- --- 
Early detection of 
recurrence or 
progression 
Clinical question not addressed by CPGs --- --- --- 
Monitoring of 
treatment response 
in advanced disease 
Clinical question not addressed by CPGs --- --- --- 
(1) CPG/total CPG: CPGs reporting the summarized information/total number of CPGs that consider the clinical question.
(2) OGD/total OGD: OGDs reporting the summarized information/total number of OGDs that consider the clinical question.
∅ The examined CPGs that consider the clinical question either do not address TMs or, if TMs are addressed, CPGs do not present explicit recommendations.
Acronyms of CPGs 
Domain 1 
Scope and 
purpose 
Domain 2 
Stakeholder 
involvement 
Domain 3 
Rigor of 
development 
Domain 4 
Clarity of 
presentation 
Domain 5 
Applicability 
Domain 6 
Editorial 
independence 
ACG 2014 58 36 67 92 25 88 
NICE 2015 93 88 96 93 72 81 
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Colorectal cancer Examined documents: 19 (10 CPGs, 9 OGDs) 
Clinical question Summary of recommendations 
Recommended 
tumor 
marker(s) 
CPG/total CPG (1) 
(CPG acronyms) 
OGD/total OGD (2)
(OGD acronyms) 
Screening of people 
at increased risk  Recommendations on TMs not available ∅ 
4/4 
(AGA 2010, NICE 2011-SU, 
SIGN 2011, USMSTF 2012) 
3/3 
(AIOM 2015, ESMO 2013-C, 
NCCN 2015-C) 
Differential 
diagnosis Recommendations on TMs not available ∅ 
5/5 
(ASCRS 2012-C, CCO 2014-CRC, 
NICE 2014, NICE 2015, 
SIGN 2011) 
4/4 
(AIOM 2015, ESMO 2012-CRC, 
ESMO 2013-C,ESMO 2013-R) 
Preoperative 
workup 
CEA should be assessed before elective 
surgery for the establishment of baseline 
values 
CEA 
∅ 
3/6 
(ASCRS 2012-C, ASCRS 2013-R, 
CCO 2014-R) 
7/7 
(AIOM 2015, EGTM 2013, 
ESMO 2012-CRC, ESMO 2013-C, 
ESMO 2013-R, NCCN 2015-C, 
NCCN 2015-R) 
At present there is insufficient evidence to 
support the routine use of other TMs such as 
CA19.9 in addition to CEA 
2/6 
(ASCRS 2012-C, ASCRS 2013-R) 
1/7 
(AIOM 2015) 
Recommendations on TMs not available ∅ 
3/6 
(AGA 2010, NICE 2014, 
SIGN 2011) 
0/7 
Reassessment after 
initial curative 
treatment 
Recommendations on TMs not available ∅ 
1/1 
(SIGN 2011) 
2/3 
(ESMO 2013-C, ESMO 2013-R) 
Early detection of 
recurrence or 
progression 
CEA should be regularly assessed at least in 
the first 3-5 years during follow-up to 
monitor for signs of recurrence  
CEA 
4/4 
(ASCRS 2012-C, ASCRS 2013-R, 
NICE 2014, SIGN 2011) 
7/8 
(AIOM 2015, ASCO 2013, 
EGTM 2013, ESMO 2012-CRC, 
ESMO 2013-C, NCCN 2015-C, 
NCCN 2015-R) 
A confirmed rise in postoperative CEA levels 
during surveillance should prompt further 
investigation for recurrent disease 
2/4 
(ASCRS 2012-C, ASCRS 2013-R) 
5/8 
(AIOM 2015, EGTM 2013, 
ESMO 2013-C, NCCN 2015-C, 
NCCN 2015-R) 
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At present there is insufficient evidence to 
support the routine use of other TMs such as 
CA19.9 in addition to CEA 
2/4 
(ASCRS 2012-C, ASCRS 2013-R) 
1/8 
(ESMO 2013-C) 
Monitoring of 
treatment 
response in 
advanced disease 
Recommendations on TMs not available ∅ 
3/3 
(ASCRS 2012-C, NICE 2014, 
SIGN 2011) 
3/7 
(AIOM 2015, ESMO 2012-CRC, 
ESMO 2013-R) 
(1) CPG/total CPG: CPGs reporting the summarized information/total number of CPGs that consider the clinical question. 
(2) OGD/total OGD: OGDs reporting the summarized information/total number of OGDs that consider the clinical question. 
∅ The examined CPGs that consider the clinical question either do not address TMs or, if TMs are addressed, CPGs do not present explicit recommendations. 
 
 
 
Acronyms of CPGs  
Domain 1 
Scope and 
purpose 
Domain 2 
Stakeholder 
involvement 
Domain 3 
Rigor of 
development 
Domain 4 
Clarity of 
presentation 
Domain 5 
Applicability 
Domain 6 
Editorial 
independence 
AGA 2010 72 33 49 78 21 54 
ASCRS 2012-C 58 33 67 83 25 33 
ASCRS 2013-R 53 36 59 81 19 38 
CCO 2014-CRC 94 53 77 75 35 100 
CCO 2014-R 97 50 83 81 38 67 
NICE 2011-SU 97 92 93 97 79 88 
NICE 2014 100 94 97 94 88 92 
NICE 2015 94 92 95 94 88 83 
SIGN 2011 86 81 78 89 73 63 
USMSTF 2012 67 36 67 69 19 50 
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Esophageal cancer Examined documents: 9 (5 CPGs, 4 OGDs) 
Clinical question Summary of recommendations Recommended tumor marker(s) 
CPG/total CPG (1) 
(CPG acronyms) 
OGD/total OGD (2)
(OGD acronyms) 
Screening of people at 
increased risk  
(Barrett's esophagus) 
Recommendations on TMs not available 
∅ 
3/3 
(AHS 2014, mep 2012, 
NHMRC 2014) 
0/0 
Differential diagnosis Recommendations on TMs not available 
∅ 
5/5 
(AHS 2014, mep 2012, 
NHMRC 2014, NICE 2015, 
STS 2013) 
3/3 
(AIOM 2015, ESMO 2013, 
NCCN 2015) 
Preoperative workup Recommendations on TMs not available 
∅ 
3/3 
(AHS 2014, NHMRC 2014, 
STS 2013) 
4/4 
(AIOM 2015, AIRO 2012, 
ESMO 2013, NCCN 2015) 
Reassessment after initial 
curative treatment Clinical question not addressed by CPGs --- --- --- 
Early detection of 
recurrence or progression Recommendations on TMs not available ∅ 
1/1 
(AHS 2014) 
4/4 
(AIOM 2015, AIRO 2012, 
ESMO 2013, NCCN 2015) 
Monitoring of treatment 
response in advanced 
disease 
Recommendations on TMs not available ∅ 1/1 
(STS 2013) 
4/4 
(AIOM 2015, AIRO 2012, 
ESMO 2013, NCCN 2015) 
(1) CPG/total CPG: CPGs reporting the summarized information/total number of CPGs that consider the clinical question.
(2) OGD/total OGD: OGDs reporting the summarized information/total number of OGDs that consider the clinical question.
∅ The examined CPGs that consider the clinical question either do not address TMs or, if TMs are addressed, CPGs do not present explicit recommendations.
Acronyms of CPGs 
Domain 1 
Scope and 
purpose 
Domain 2 
Stakeholder 
involvement 
Domain 3 
Rigor of 
development 
Domain 4 
Clarity of 
presentation 
Domain 5 
Applicability 
Domain 6 
Editorial 
independence 
AHS 2014 92 44 68 67 58 79 
mep 2012 72 67 65 75 33 67 
NHMRC 2014 83 67 68 81 44 75 
NICE 2015 89 97 90 92 73 79 
STS 2013 58 44 69 69 25 50 
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Gastric cancer Examined documents: 8 (3 CPGs, 5 OGDs) 
Clinical question Summary of recommendations 
Recommended 
tumor 
marker(s) 
CPG/total CPG (1) 
(CPG acronyms) 
OGD/total OGD (2)
(OGD acronyms) 
Screening of people 
at increased risk  
Recommendations on TMs not available 
∅ 
1/1 
(ACCC 2009) 
1/1 
(NCCN 2015) 
Differential 
diagnosis 
Recommendations on TMs not available 
∅ 
1/1 
(NICE 2015) 
2/2 
(AIOM 2015, ESMO 2013) 
Preoperative 
workup 
Recommendations on TMs not available 
∅ 
1/1 
(ACCC 2009) 
4/5 
(AIOM 2015, EGTM 2013, 
ESMO 2013, NCCN 2015) 
Reassessment after 
initial curative 
treatment 
Clinical question not addressed by CPGs --- --- --- 
Early detection of 
recurrence or 
progression 
Determining TMs for the follow-up of patients 
operated on for gastric carcinoma is not worthwhile 
because it does not lead to clinical benefit  
None 
1/1 
(ACCC 2009) 
0/4 
Monitoring of 
treatment response 
in advanced disease 
Recommendations on TMs not available 
∅ 2/2 
(ACCC 2009, CCO 2014) 
4/4 
(AIOM 2015, AIRO 2012, 
ESMO 2013, NCCN 2015) 
(1) CPG/total CPG: CPGs reporting the summarized information/total number of CPGs that consider the clinical question.
(2) OGD/total OGD: OGDs reporting the summarized information/total number of OGDs that consider the clinical question.
∅ The examined CPGs that consider the clinical question either do not address TMs or, if TMs are addressed, CPGs do not present explicit recommendations.
Acronyms of CPGs 
Domain 1 
Scope and 
purpose 
Domain 2 
Stakeholder 
involvement 
Domain 3 
Rigor of 
development 
Domain 4 
Clarity of 
presentation 
Domain 5 
Applicability 
Domain 6 
Editorial 
independence 
ACCC 2009 83 61 71 75 33 50 
CCO 2014 83 56 81 75 42 71 
NICE 2015 89 97 91 89 71 83 
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Hepatocellular carcinoma (HCC) Examined documents: 12 (6 CPGs, 6 OGDs) 
Clinical question Summary of recommendations 
Recommended 
tumor 
marker(s) 
CPG/total CPG (1) 
(CPG acronyms) 
OGD/total OGD (2)
(OGD acronyms) 
Screening of people at 
increased risk  
Surveillance of patients in the high-risk group is 
based on periodic ultrasonography combined with 
measurement of AFP 
AFP 
∅ 
2/3 
(JSH 2013, NICE 2013-HBV) 
1/6 
(NCCN 2015) 
Recommendations on TMs not available 1/3 (MCC 2011) 
1/6 
(ESMO 2012) 
Supplementary information: Screening for HCC 
should use ultrasonography alone. AFP (and other 
TMs) not indicated for surveillance strategy because 
of low sensitivity (lower than ultrasonography) and 
low specificity 
1/3 
(MCC 2011) 
5/6 
(AIOM 2015, AIRO 2012, 
AISF 2013, EASL-
EORTC 2012, ESMO 2012) 
Differential diagnosis 
Recommendations on TMs not available 
∅ 
4/4 
(ACG 2014-FLL, JSH 2013, 
MCC 2011, NICE 2015) 
3/6 
(AIOM 2015, AIRO 2012, 
EASL-EORTC 2012) 
Supplementary information n. 1: The diagnostic 
workup of a patient with suspected HCC includes 
serum AFP measurement 
1/4 
(ACG 2014-FLL) 
2/6 
(AIOM 2015, ESMO 2012) 
Supplementary information n. 2: No primary care 
evidence was identified pertaining to the diagnostic 
accuracy of AFP in patients with suspected liver 
cancer where the clinical responsibility was retained 
by primary care 
1/4 
(NICE 2015) 
0/6 
Preoperative workup 
Recommendations on TMs not available ∅ 
2/2 
(JSH 2013, MCC 2011) 
3/6 
(AIRO 2012, EASL-
EORTC 2012, ESMO 2012) 
Published in final edited form as: Int J Biol Markers. 2016 Dec 23;31(4):e332-e367. doi: 10.5301/jbm.5000251.
22 
Liver transplant 
priority and delisting 
policies 
Periodic waiting-list monitoring should be performed 
by imaging and AFP measurement 
AFP 
∅ 
1/3 
(OLT4HCG 2012) 
2/4 
(AISF 2013, EASL-
EORTC 2012) 
Increased AFP levels and/or changes in serum AFP 
over time may predict the risk of dropout from liver 
transplant waiting list 
1/3 
(OLT4HCG 2012) 
2/4 
(AISF 2013, EASL-
EORTC 2012) 
Recommendations on TMs not available 2/3 (JSH 2013, MCC 2011) 
2/4 
(AIOM 2015, NCCN 2015) 
Reassessment after 
initial curative 
treatment 
Clinical question not addressed by CPGs --- --- --- 
Early detection of 
recurrence or 
progression 
Monitoring after liver transplant and palliative 
treatments may include periodic AFP measurements AFP 
1/1 
(OLT4HCG 2012) 
3/5 
(AISF 2013, ESMO 2012, 
NCCN 2015) 
Monitoring of 
treatment response in 
advanced disease 
Recommendations on TMs not available ∅ 
2/2 
(JSH 2013, MCC 2011) 
5/6 
(AIOM 2015, AIRO 2012, 
AISF 2013, EASL-
EORTC 2012, NCCN 2015) 
(1) CPG/total CPG: CPGs reporting the summarized information/total number of CPGs that consider the clinical question.
(2) OGD/total OGD: OGDs reporting the summarized information/total number of OGDs that consider the clinical question.
∅ The examined CPGs that consider the clinical question either do not address TMs or, if TMs are addressed, CPGs do not present explicit recommendations.
 Inconsistent recommendations on TMs in the clinical question are reported by different CPGs. 
Acronyms of CPGs 
Domain 1 
Scope and 
purpose 
Domain 2 
Stakeholder 
involvement 
Domain 3 
Rigor of 
development 
Domain 4 
Clarity of 
presentation 
Domain 5 
Applicability 
Domain 6 
Editorial 
independence 
ACG 2014-FLL 58 42 70 89 33 88 
JSH 2013 75 44 60 81 40 29 
MCC 2011 56 44 63 72 33 58 
NICE 2013-HBV 94 89 97 97 81 88 
NICE 2015 89 97 91 86 73 83 
OLT4HCG 2012 56 61 68 75 31 50 
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Pancreatic cancer Examined documents: 7 (4 CPGs, 3 OGDs) 
Clinical question Summary of recommendations 
Recommended 
tumor 
marker(s) 
CPG/total CPG (1) 
(CPG acronyms) 
OGD/total OGD (2)
(OGD acronyms) 
Screening Clinical question not addressed by CPGs --- --- --- 
Differential diagnosis 
Recommendations on TMs not available 
∅ 
2/2 
(ISGPS 2014-A, NICE 2015) 
3/3 
(AIOM 2015, ESMO 2012, 
NCCN 2015) 
Supplementary information: CA 19.9 may be 
falsely positive in cases of biliary obstruction 
(regardless of etiology) and in cases of 
infection or inflammation of the biliary tract 
(NCCN 2015) 
1/2 
(ISGPS 2014-A) 
3/3 
(AIOM 2015, ESMO 2012, 
NCCN 2015) 
Preoperative workup CA19.9 may be included in standard 
preoperative diagnostics for patients with 
borderline resectable pancreatic cancer CA19.9 
∅ 
1/3 
(ISGPS 2014-B) 
0/3 
Supplementary information: Elevated 
preoperative CA19.9 may have negative 
prognostic value 
2/3 
(ISGPS 2014-B, S3 2014) 
3/3 
(AIOM 2015, ESMO 2012, 
NCCN 2015) 
Recommendations on TMs not available 
2/3 
(ISGPS 2014-A, S3 2014) 
1/3 
(ESMO 2012) 
Reassessment after initial 
curative treatment Clinical question not addressed by CPGs --- 
--- --- 
Early detection of 
recurrence or progression Clinical question not addressed by CPGs --- --- --- 
Monitoring of treatment 
response in advanced 
disease 
Recommendations on TMs not available ∅ 
1/1 
(S3 2014) 
2/3 
(ESMO 2012, NCCN 2015) 
(1) CPG/total CPG: CPGs reporting the summarized information/total number of CPGs that consider the clinical question.
(2) OGD/total OGD: OGDs reporting the summarized information/total number of OGDs that consider the clinical question.
∅ The examined CPGs that consider the clinical question either do not address TMs or, if TMs are addressed, CPGs do not present explicit recommendations.
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Acronyms of CPGs 
Domain 1 
Scope and 
purpose 
Domain 2 
Stakeholder 
involvement 
Domain 3 
Rigor of 
development 
Domain 4 
Clarity of 
presentation 
Domain 5 
Applicability 
Domain 6 
Editorial 
independence 
ISGPS 2014-A 81 44 58 67 27 42 
ISGPS 2014-B 81 44 59 67 27 42 
NICE 2015 89 97 91 89 73 88 
S3 2014 58 44 60 69 27 63 
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DETAILED SUMMARY TABLES 
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DETAILED SUMMARY TABLES - Users’ instructions 
Definition and target audience 
Detailed Summary Tables are tables prepared for every tumor type which report recommendations and supplementary information from different 
guidance documents with enough details to be useful for health care providers, policy makers (for potential adaptation to specific settings) and 
staff developing educational material informed by available evidence. 
Structure 
Total number of selected documents (number of CPGs, number of OGDs) 
Clinical 
question CPG OGD Summary of recommendations Supplementary information 
The 
different 
clinical 
questions 
are 
reported 
Number 
of CPGs 
addressing 
the clinical 
question 
Number 
of OGDs 
addressing 
the clinical 
question 
Recommendations from CPGs and from OGDs 
that are consistent with those of CPGs  
Only those parts of the text explicitly defined as 
recommendations and clearly recognizable as 
such were considered 
Similar recommendations and supplementary 
information from different guidance documents 
are reported once, followed by the acronyms of 
the guidance documents by which they are 
provided  
Acronyms of CPGs are printed in bold blue type, 
those of OGDs are printed in regular type 
Useful supplementary information for the clinical 
application of TMs from both CPGs and OGDs are 
summarized (e.g., suggested cutoff points, timing of 
serial sample monitoring, causes of false positive or 
false negative TM results)  
Recommendations from OGDs that are inconsistent 
with those of CPGs are reported 
Advice for clinical practice not declared or not 
recognizable as recommendation in the document is 
reported  
Acronyms of CPGs are printed in bold blue type, those 
of OGDs are printed in regular type 
Published in final edited form as: Int J Biol Markers. 2016 Dec 23;31(4):e332-e367. doi: 10.5301/jbm.5000251.
27 
 
Biliary cancer            Examined documents: 7 (2 CPGs, 5 OGDs) 
Clinical 
question CPG OGD Summary of recommendations 
(1) Supplementary information (2) 
Screening of 
people at 
increased risk  
1 2 Clinical question considered, but TMs not 
addressed (ACG 2014) 
The current evidence does not support routine screening for 
cholangiocarcinoma in asymptomatic patients with underlying 
primary sclerosing cholangitis (ACG 2014, AASLD 2010, SIGE 2010) 
Patients with primary sclerosing cholangitis should undergo careful 
surveillance for cholangiocarcinoma development mainly during the 
first 2 years of follow-up (SIGE 2010) 
Surveillance with CA19.9 and one imaging technique (CT or MRI) is at 
present the suggested approach (SIGE 2010)  
No study has demonstrated any value for the serum CA19.9 test as a 
screening modality in asymptomatic primary sclerosing cholangitis 
(AASLD 2010, SIGE 2010) 
Differential 
diagnosis 
2 5 Clinical question considered, no explicit 
recommendations on TMs provided 
(ACG 2014, NICE 2015, AIRO 2012, NCCN 2015, 
SIGE 2010)  
CA19.9 is a serum marker that can be measured to identify cases 
with intrahepatic cholangiocarcinoma in patients with focal liver 
lesions, but it has low specificity and sensitivity (ACG 2014, AASLD 2010, 
AIRO 2012, SIGE 2010) 
No primary care evidence was identified pertaining to the diagnostic 
accuracy of … CA19.9 in patients with suspected gallbladder cancer 
where the clinical responsibility was retained by primary care 
(NICE 2015) 
CA19.9 can be elevated in patients with diseases other than biliary 
cancer (AASLD 2010, AIRO 2012, NCCN 2015): 
- other malignancies (e.g., gastric or pancreatic cancer) 
- benign conditions (bacterial cholangitis, cholestatic jaundice, 
gallbladder lithiasis) 
Patients negative for the Lewis antigen will not have an elevated 
serum CA19.9 level despite having cholangiocarcinoma (AASLD 2010) 
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Clinical question considered, but TMs not addressed (ESMO 2011) 
Preoperative 
workup 
1 3 Clinical question considered, but TMs not 
addressed (ACG 2014)  
CEA and CA19.9 could be considered as part of the initial workup (in 
conjunction with imaging studies) (AIRO 2012, NCCN 2015) 
Clinical question considered, no explicit recommendations on TMs 
provided (SIGE 2010) 
Reassessment 
after initial 
curative 
treatment 
0 1 Clinical question not addressed by CPGs Clinical question considered, but TMs not addressed (ESMO 2011) 
Early detection 
of recurrence or 
progression 
0 3 Clinical question not addressed by CPGs Clinical question considered, no explicit recommendations on TMs 
provided (AIRO 2012, NCCN 2015) 
Clinical question considered, but TMs not addressed (ESMO 2011) 
Monitoring of 
treatment 
response in 
advanced 
disease 
0 3 Clinical question not addressed by CPGs Clinical question considered, but TMs not addressed (ESMO 2011) 
In the event of disease relapse or progression CEA and CA19.9 could 
be considered as part of the initial workup … in conjunction with 
imaging studies (NCCN 2015) 
CA19.9 testing can be considered after biliary decompression 
(NCCN 2015) 
Clinical question considered, but criteria to monitor treatment 
response (including TMs) not addressed (SIGE 2010) 
(1) Recommendations from CPGs and from OGDs, if consistent with those of CPGs.
(2) Supplementary information from both CPGs and OGDs, and recommendations from OGDs that are inconsistent with those of CPGs.
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Colorectal cancer            Examined documents: 19 (10 CPGs, 9 OGDs) 
Clinical 
question CPG OGD Summary of recommendations 
(1) Supplementary information (2) 
Screening of 
people at 
increased risk  
4 3 Clinical question considered, but TMs not 
addressed (AGA 2010, NICE 2011-SU, SIGN 2011, 
USMSTF 2012, AIOM 2015, ESMO 2013-C, NCCN 2015-C) 
 
Differential 
diagnoses 
5 4 Clinical question considered, but TMs not 
addressed (ASCRS 2012-C, CCO 2014-CRC, NICE 2014, 
NICE 2015, SIGN 2011, AIOM 2015, ESMO 2012-CRC, 
ESMO 2013-R)  
Clinical question considered, no explicit recommendations on 
TMs provided (ESMO 2012-C) 
CEA has low predictive value for diagnosis in asymptomatic 
patients due to its relatively low sensitivity and specificity 
(ESMO 2013-C) 
Preoperative 
workup 
6 7 CEA should be assessed before elective surgery 
for the establishment of baseline values 
(ASCRS 2012-C, ASCRS 2013-R, CCO 2014-R, AIOM 2015, 
EGTM 2013, ESMO 2012-CRC, ESMO 2013-C, ESMO 2013-
R, NCCN 2015-C, NCCN 2015-R) 
At present there is insufficient evidence to 
support the routine use of other TMs such as 
CA19.9 (ASCRS 2012-C, ASCRS 2013-R, AIOM 2015) 
Clinical question considered, but TMs not 
addressed (AGA 2010, NICE 2014, SIGN 2011) 
Increased levels of CEA have been correlated with poorer 
prognosis (ASCRS 2012-C, ASCRS 2013-R, AIOM 2015, EGTM 2013, 
ESMO 2013-C) 
Data are insufficient to justify the use of a high preoperative 
CEA level as an indication for adjuvant therapy (ASCRS 2012-C, 
ASCRS 2013-R, AIOM 2015, EGTM 2013) 
 
Reassessment 
after initial 
curative 
treatment 
1 3 Clinical question considered, but TMs not 
addressed (SIGN 2011, ESMO 2013-R) 
An increased preoperative value not normalized after 1 month 
following surgical resection may indicate persistent disease 
(AIOM 2015, ESMO 2013-C) 
Clinical question considered, no explicit recommendations on 
TMs provided (ESMO 2013-C) 
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Early 
detection of 
recurrence or 
progression 
4 8 CEA should be regularly assessed during follow-
up to monitor for signs of recurrence 
(ASCRS 2012-C, ASCRS 2013-R, NICE 2014, SIGN 2011, 
AIOM 2015, ASCO 2013, EGTM 2013, ESMO 2012-CRC, 
ESMO 2013-C, NCCN 2015-C, NCCN 2015-R) 
A confirmed rise in the postoperative CEA 
during surveillance should prompt further 
investigation for recurrent disease (ASCRS 2012-C, 
ASCRS 2013-R, AIOM 2015, EGTM 2013, ESMO 2013-C, 
NCCN 2015-C, NCCN 2015-R) 
At present there is insufficient evidence to 
support the routine use of other TMs such as 
CA19.9 (ASCRS 2012-C, ASCRS 2013-R, ESMO 2013-C) 
Reported schedule(s) of CEA determination 
- at least every 6 months in the first 3 years (NICE 2014)
- every 2-3 months in the first 3 years, every 6 months at years
4 and 5 (EGTM 2013)
- every 3 months in the first 3 years, every 6 months at years 4
and 5 (ESMO 2012-CRC)
- every 3-4 months in the first 3 years, every 6 months at years
4 and 5 (AIOM 2015)
- every 3-6 months for 5 years. Patients at higher risk of
recurrence should be considered for testing in the more
frequent end of the range (ASCO 2013)
- every 3-6 months in the first 2 years, every 6 months at years
4 and 5 (NCCN 2015-C, NCCN 2015-R)
- every 3-6 months in the first 3 years, every 6-12 months at
years 4 and 5 (ESMO 2013-C)
- evidence does not consent to recommend one specific
protocol, but a pragmatic protocol of follow-up is
recommended (NICE 2014, SIGN 2011)
Caution should be exercised in interpreting CEA levels, as both 
false-positive rates of CEA elevation (7%-16%) and false-
negative rates (up to 40%) have been reported (EGTM 2013, 
ESMO 2013-C) 
In rectal cancer, clinical, laboratory (including CEA) and 
radiological examinations are of unproven benefit and should 
be restricted to patients with suspicious symptoms (ESMO 2013-
R) 
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Monitoring of 
treatment 
response in 
advanced 
disease 
3 7 Clinical question considered, but TMs not 
addressed (NICE 2014) 
Clinical question considered, but criteria to 
monitor treatment response (including TMs) 
not addressed (ASCRS 2012-C, SIGN 2011, AIOM 2015, 
ESMO 2013-R) 
Clinical question considered, no explicit recommendations on 
TMs provided (ESMO 2012-CRC) 
CEA >50 ng/mL is an established poor prognostic factors in 
advanced CRC (ESMO 2012-CRC) 
CEA flare and drop are predictive factors of response to 
treatment in advanced CRC (ESMO 2012-CRC) 
CEA – if initially elevated – should be measured before and 
periodically during chemotherapy for metastatic disease 
(EGTM 2013, ESMO 2014-mCRC) 
CEA should be included in the initial workup of suspected or 
proven metastatic disease (NCCN 2015-C, NCCN 2015-R) 
Use of CEA is as accurate as CT imaging for assessing the 
response of colorectal cancer liver metastasis to chemotherapy 
(EGTM 2013) 
Reported schedule of patient re-evaluation: 
- patients should be re-evaluated every 2-3 months if
chemotherapy is continued (ESMO 2014-mCRC)
(1) Recommendations from CPGs and from OGDs, if consistent with those of CPGs.
(2) Supplementary information from both CPGs and OGDs, and recommendations from OGDs that are inconsistent with those of CPGs.
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Esophageal cancer Examined documents: 9 (5 CPGs, 4 OGDs) 
Clinical question CPG OGD Summary of recommendations (1) Supplementary information (2) 
Screening of 
people at 
increased risk 
(Barrett's 
esophagus) 
3 0 Clinical question considered, but TMs not addressed 
(AHS 2014, mep 2012, NHMRC 2014) 
Differential 
diagnosis 
5 3 Clinical question considered, but TMs not addressed 
(AHS 2014, mep 2012, NHMRC 2014, NICE 2015, STS 2013, 
AIOM 2015, ESMO 2013, NCCN 2015) 
Preoperative 
workup 
3 4 Clinical question considered, but TMs not addressed 
(AHS 2014, NHMRC 2014, STS 2013, AIOM 2015, AIRO 2012, 
ESMO 2013, NCCN 2015) 
Reassessment 
after initial 
curative 
treatment 
0 4 Clinical question not addressed by CPGs Clinical question considered, but TMs not addressed 
(AIOM 2015, AIRO 2012, ESMO 2013, NCCN 2015) 
Early detection 
of recurrence or 
progression 
1 4 Clinical question considered, but TMs not addressed 
(AHS 2014, AIOM 2015, AIRO 2012, ESMO 2013, NCCN 2015) 
Monitoring of 
treatment 
response in 
advanced disease 
1 4 Clinical question considered, but TMs not addressed 
(STS 2013, AIOM 2015, AIRO 2012, ESMO 2013, NCCN 2015) 
(1) Recommendations from CPGs and from OGDs, if consistent with those of CPGs.
(2) Supplementary information from both CPGs and OGDs, and recommendations from OGDs that are inconsistent with those of CPGs.
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Gastric cancer            Examined documents: 8 (3 CPGs, 5 OGDs) 
Clinical 
question CPG OGD Summary of recommendations 
(1) Supplementary information (2) 
Screening of 
people at 
increased risk  
1 1 Clinical question considered, but TMs not addressed 
(ACCC 2009, NCCN 2015) 
 
Differential 
diagnosis 
1 2 Clinical question considered, but TMs not addressed 
(NICE 2015, AIOM 2015, ESMO 2013) 
 
Preoperative 
workup 
1 5 Clinical question considered, but TMs not addressed 
(ACCC 2009, AIOM 2015, ESMO 2013, NCCN 2015) 
CEA and CA19.9 may be considered (AIRO 2012) 
Clinical question considered, no explicit recommendations on 
TMs provided (EGTM 2013) 
Reassessment 
after initial 
curative 
treatment 
0 1 Clinical question not addressed by CPGs Clinical question considered, but TMs not addressed 
(NCCN 2015) 
Early 
detection of 
recurrence or 
progression 
1 4 Determining TMs for the follow-up of patients 
operated on for gastric carcinoma is not worthwhile 
because it does not lead to clinical benefit 
(ACCC 2009) 
CEA and CA19.9 may be considered (AIOM 2015, AIRO 2012) 
TMs contribute to the earlier detection of recurrences after 
surgery with curative intent; however, this is without 
therapeutic consequences (ACCC 2009, AIOM 2015) 
Clinical question considered, but TMs not addressed 
(ESMO 2013, NCCN 2015) 
Monitoring of 
treatment 
response in 
advanced 
disease 
2 4 Clinical question considered, but criteria to monitor 
treatment response (including TMs) not addressed 
(ACCC 2009, CCO 2014, AIOM 2015, AIRO 2012, ESMO 2013, 
NCCN 2015) 
 
(1) Recommendations from CPGs and from OGDs, if consistent with those of CPGs. 
(2) Supplementary information from both CPGs and OGDs, and recommendations from OGDs that are inconsistent with those of CPGs. 
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Hepatocellular carcinoma (HCC) Examined documents: 12 (6 CPGs, 6 OGDs) 
Clinical 
question CPG OGD Summary of recommendations 
(1) Supplementary information (2) 
Screening of 
people at 
increased risk 
3 6 Surveillance of patients in the high-risk 
group is based on periodic 
ultrasonography combined with 
measurement of AFP (JSH 2013, 
NICE 2013-HBV, NCCN 2015) 
Do not offer surveillance for HCC in 
people with low risk (NICE 2013-HBV) 
Clinical question considered, no explicit 
recommendations on TMs provided 
(MCC 2011, ESMO 2012)  
Risk categories for surveillance strategy: cirrhosis associated with hepatitis B or 
alcohol, genetic hemochromatosis, autoimmune hepatitis, nonalcoholic 
steatohepatitis, primary biliary cirrhosis, alpha-1 antitrypsin deficiency; individuals 
without cirrhosis who are HBV carriers or have other risk factors (e.g., active viral 
replication, high HBV DNA concentration, family history of HCC); patients with 
chronic HCV infection and severe liver fibrosis (NICE 2013-HBV, AIRO 2012, NCCN 2015)  
AFP (and other TMs) not indicated for surveillance strategy because of low 
sensitivity (lower than ultrasonography) and low specificity (MCC 2011, AIOM 2015, 
AIRO 2012, AISF 2013, EASL-EORTC 2012, ESMO 2012) 
Screening for HCC should use ultrasonography alone (MCC 2011, AIOM 2015, AISF 2013, 
EASL-EORTC 2012, ESMO 2012) 
Combination of AFP and other markers (AFP-L3, DCP) is suggested (JSH 2013) 
The use of other markers (DCP, AFP-L3) in combination with AFP is not suggested 
(MCC 2011, AIRO 2012, EASL-EORTC 2012, NCCN 2015) 
AFP should be used only in combination with ultrasonography (AIRO 2012) 
AFP can be used autonomously only if ultrasonography is not feasible (AIOM 2015) 
Reported surveillance schedule(s) of ultrasonography and AFP determination: 
- every 3-4 months in people at extremely high risk; every 6 months in those at
high risk (JSH 2013)
- every 6 months in people at high and intermediate risk (NICE 2013-HBV)
- every 6-12 months (NCCN 2015)
Elevated AFP found during surveillance is not necessary related to cancer 
(MCC 2011) 
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AFP can also be elevated in intrahepatic cholangiocarcinoma and in some cases of 
metastasis from colon cancer (NCCN 2015)  
Differential 
diagnosis 
4 6 Clinical question considered, no explicit 
recommendations on TMs provided 
(ACG 2014-FLL, NICE 2015, AIOM 2015, EASL-
EORTC 2012) 
Clinical question considered, but TMs 
not addressed (JSH 2013, MCC 2011, 
AIRO 2012) 
The diagnostic workup of a patient with suspected HCC includes serum AFP 
measurement (ACG 2014-FLL, AIOM 2015, ESMO 2012) 
AFP measurement should not be considered a diagnostic test for HCC in the 
assessment of focal liver lesions (AISF 2013) 
No primary care evidence was identified pertaining to the diagnostic accuracy of 
ultrasound, CT, MRI or AFP in patients with suspected liver cancer where the 
clinical responsibility was retained by primary care (NICE 2015) 
AFP has low diagnostic sensitivity and specificity (AIOM 2015, AISF 2013, NCCN 2015) 
AFP may also be elevated in intrahepatic cholangiocarcinoma, some metastases 
from colon cancer, and germ cell tumors (AIOM 2015, AISF 2013, NCCN 2015) 
Preoperative 
workup 
2 6 Clinical question considered, no explicit 
recommendations on TMs provided 
(MCC 2011, EASL-EORTC 2012) 
Clinical question considered, but TMs 
not addressed (JSH 2013, AIRO 2012, 
ESMO 2012) 
Elevated AFP levels, possibly integrated into prognostic algorithms, may offer 
prognostic information (e.g., CLIP score) (MCC 2011, AIOM 2015, AISF 2013, EASL-
EORTC 2012, NCCN 2015) 
AFP cannot be used to guide therapeutic decisions based on the best scientific 
evidence currently available (AISF 2013) 
Liver 
transplant 
priority and 
delisting 
policies 
3 4 Periodic waiting-list monitoring should 
be performed by imaging and AFP 
measurement (OLT4HCG 2012)  
AFP concentrations add prognostic 
information (OLT4HCG 2012) 
Clinical question considered, but 
criteria to assess dropout (including 
TMs) not addressed (JSH 2013, MCC 2011, 
AIOM 2015, NCCN 2015) 
The presence of high AFP concentrations seem to predict a higher risk of dropout 
(OLT4HCG 2012, AISF 2013, EASL-EORTC 2012) 
Increased AFP levels (see cutoff values below) and/or changes in serum AFP over 
time may be useful to evaluate the risk of dropout from liver transplant waiting list 
(AISF 2013, EASL-EORTC 2012) 
- higher than 200 ng/mL (EASL-EORTC 2012) 
- higher than 400 ng/mL (OLT4HCG 2012)  
Biomarkers other than AFP cannot yet be used for clinical decision-making 
regarding liver transplant for HCC (OLT4HCG 2012) 
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Reassessment 
after initial 
curative 
treatment 
0  5 Clinical question not addressed by CPGs In patients with markedly elevated (>200-400 ng/mL) or progressively increasing 
levels, AFP may provide useful prognostic information to assess the response to 
locoregional and systemic treatments (AISF 2013, EASL-EORTC 2012, NCCN 2015) 
AFP levels may be helpful, particularly in the case of not easily measurable disease, 
but should not be used as the only determinant for treatment decisions 
(ESMO 2012) 
Clinical question considered, no explicit recommendations on TMs provided 
(AIRO 2012, EASL-EORTC 2012, NCCN 2015) 
Early detection 
of recurrence 
or progression 
1 5 Monitoring after liver transplant and 
palliative treatments may include 
periodic AFP measurements 
(OLT4HCG 2012, ESMO 2012, NCCN 2015)  
An increase in AFP during follow-up may suggest HCC recurrence. Nevertheless, 
AFP assessment cannot replace radiological surveillance follow-up (AISF 2013) 
AFP levels may be helpful but should not be used as the only determinant for 
treatment decisions (ESMO 2012) 
Clinical question considered, no explicit recommendations on TMs provided 
(AIRO 2012, AISF 2013) 
Clinical question considered, but TMs not addressed (AIOM 2015) 
Monitoring of 
treatment 
response in 
advanced 
disease 
2  6  Clinical question considered, but 
criteria to monitor treatment response 
(including TMs) not addressed (JSH 2013, 
MCC 2011, AIOM 2015, AIRO 2012, AISF 2013) 
AFP determination may be helpful for assessment of response, particularly in the 
case of not easily measurable disease, but should not be used as the only 
determinant for treatment decisions (EASL-EORTC 2012, ESMO 2012, NCCN 2015) 
Clinical question considered, no explicit recommendations on TMs provided (EASL-
EORTC 2012, NCCN 2015) 
(1) Recommendations from CPGs and from OGDs, if consistent with those of CPGs. 
(2) Supplementary information from both CPGs and OGDs, and recommendations from OGDs that are inconsistent with those of CPGs. 
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Pancreatic cancer Examined documents: 7 (4 CPGs, 3 OGDs)
Clinical question CPG OGD Summary of recommendations (1) Supplementary information (2) 
Screening 0 2 Clinical question not addressed by CPGs Clinical question considered, but TMs not addressed 
(ESMO 2012)  
Clinical question considered, no explicit recommendations 
on TMs provided (NCCN 2015) 
Differential 
diagnosis 
2 3 Clinical question considered, no explicit 
recommendations on TMs provided (ISGPS 2014-A, 
NICE 2015, AIOM 2015, ESMO 2012, NCCN 2015) 
No primary care evidence was identified pertaining to the 
diagnostic accuracy of TMs (CA19.9 and CA72-4) in patients 
with suspected pancreatic cancer where the clinical 
responsibility was retained by primary care (NICE 2015)  
Serum TMs (CA19.9, CEA) … are useful only when they are 
positive. When negative, they do not aid in determining the 
nature of the suspicious lesion and therefore have little 
influence on the decision to proceed with 
exploration/resection or not (ISGPS 2014-A) 
CA19.9 is of limited diagnostic value since it is not specific 
for pancreatic cancer (ESMO 2012) 
CA19.9 has good diagnostic sensitivity and specificity in 
symptomatic patients (NCCN 2015) and in those with 
advanced disease (AIOM 2015) 
CA19.9 may be falsely positive in cases of biliary obstruction 
(regardless of etiology) (ISGPS 2014-A, AIOM 2015, ESMO 2012, 
NCCN 2015) and in cases of biliary infection (cholangitis) or 
inflammation (NCCN 2015) 
CA19.9 may be undetectable in Lewis antigen-negative 
patients with pancreatic cancer, who are unable to 
synthesize CA19.9 (ESMO 2012, NCCN 2015) 
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Preoperative 
workup 
3 3 Clinical question considered, no explicit 
recommendations on TMs provided (ISGPS 2014-A, 
S3 2014, ESMO 2012) 
CA19.9 may be included in standard preoperative 
diagnostics for patients with borderline 
resectable pancreatic cancer to assess potential 
benefits in survival with surgery but not for 
prediction of resectability (ISGPS 2014-B) 
Serum CA19.9 level alone is not advocated for determining 
operability in pancreatic cancer (ISGPS 2014-A) 
Elevated preoperative CA19.9 has negative prognostic value 
(ISGPS 2014-B, AIOM 2015, NCCN 2015) but must be evaluated 
with caution because the evidence is based on retrospective 
cohort analyses (ISGPS 2014-B) 
Elevated preoperative CA19.9 levels correlate with 
advanced stage (ESMO 2012, NCCN 2015) including peritoneal 
carcinosis (S3 2014) 
CA19.9 may be falsely positive in cases of biliary obstruction 
(regardless of etiology) and in cases of biliary infection 
(cholangitis) or inflammation (NCCN 2015) 
CA19.9 may be undetectable in Lewis antigen-negative 
patients with pancreatic cancer, who are unable to 
synthesize CA19.9 (ESMO 2012, NCCN 2015) 
Preoperative measurement of CA19.9 is therefore best 
performed when biliary decompression is complete and 
bilirubin is normal. If biliary decompression is not 
performed in a jaundiced patient, CA19.9 levels can be 
assessed but do not represent an accurate baseline 
(NCCN 2015) 
CA19.9 should be measured before surgery (AIOM 2015, 
NCCN 2015) 
Reassessment after 
initial curative 
treatment 
0 2 Clinical question not addressed by CPGs CA19.9 should be measured following surgery immediately 
prior to administration of adjuvant therapy (AIOM 2015, 
NCCN 2015)  
Low postoperative serum CA19.9 levels or a serial decrease 
in CA19.9 levels following surgery have been found to be 
prognostic for survival (AIOM 2015, NCCN 2015) 
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Early detection of 
recurrence or 
progression 
0 3 Clinical question not addressed by CPGs Assessment of CA19.9 could be performed periodically 
during follow-up (AIOM 2015, ESMO 2012, NCCN 2015) 
Reported schedule(s) of CA19.9 measurement: 
- every 3 months for 2 years if preoperative levels were
elevated (ESMO 2012)
- every 3-6 months for 2 years (NCCN 2015)
- every 6 months for 3 years (AIOM 2015)
No data are available to show that earlier treatment of 
recurrences following detection by increased TM levels or 
CT scan leads to better patient outcomes (NCCN 2015)  
Monitoring of 
treatment response 
in advanced 
disease 
1 3 Clinical question considered, but criteria to 
monitor therapy response (including TMs) not 
addressed (S3 2014) 
CA19.9 can be periodically measured during the treatment 
of advanced disease (AIOM 2015)  
Clinical question considered, no explicit recommendations 
on TMs provided (NCCN 2015) 
Change in CA19.9 levels during chemotherapy in patients 
with advanced disease has been shown to be useful for 
evaluating the benefit of treatment, although the data are 
not entirely consistent (NCCN 2015) 
Clinical question considered, but TMs not addressed 
(ESMO 2012) 
(1) Recommendations from CPGs and from OGDs, if consistent with those of CPGs.
(2) Supplementary information from both CPGs and OGDs, and recommendations from OGDs that are inconsistent with those of CPGs.
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